Neurotechnology firm behind implantable brain–computer interfaces
The Guardian, Business Insider UK, and BBC Business report that leaders in AI say momentum is unstoppable, with Musk predicting AI may surpass human intelligence in about five years. They emphasise abundance ahead but warn of risks, urging collaboration and safety measures among firms.
SpaceX has floated on Nasdaq under the ticker SPCX, raising about $75 billion at $135 a share and debuting with a market value above $2 trillion. The newly public group combines SpaceX's rocket and Starlink businesses with xAI and X. Investors have driven strong demand despite losses and questions about unproven projects such as orbital data centres and Mars plans.
SpaceX has gone public in the largest IPO in history, pushing Elon Musk toward trillionaire status as the company outlines ambitious plans—from data centers in space to lunar bases—while investors weigh the feasibility and risks amid a sprawling empire.
Investors and analysts are weighing the possibility of a SpaceX–Tesla merger as both firms push ambitious AI and hardware programs. SpaceX’s IPO has underscored Elon Musk’s unique control of multiple unicorns, while observers debate whether a combined entity would unlock synergies or raise legal hurdles.
South Korea’s Kospi has surged and then tumbled in line with AI-driven moves by Samsung and SK Hynix. Regulators have paused leveraged ETFs as retail traders chase high-risk bets, while global investors watch the country as a barometer for AI demand.
SpaceX’s stock has fallen below its $135 initial-public-offering price, erasing a portion of post-IPO gains. Investors weigh near-term catalysts, including earnings and unlocking shares, against long-term growth bets in AI, Starlink, and ascent in space activities. Analysts remain split on valuation compared with fundamentals.
Science’s PRIMA device, a bio-hybrid brain sensor vision aid, has FDA designation and could begin patient procedures in Germany as trials continue. Analysts say the company seeks sustainable revenue to fund long-term bio-hybrid work, with first procedures anticipated this fall.